In a study published in the Journal of clinical oncology, Oral #SERD, #Elacestrant significantly improved PFS compared to standard of care (SOC) in patients with metastatic ER+ #breast_cancer. The randomized phase III, EMERALD trial randomized patients with ER+/HER2- metastatic breast cancer who progressed on a CDK4/6 inhibitor and at least 2 lines of endocrine therapy and received no more than 1 line of chemotherapy to receive either SOC endocrine therapy versus Elacestrant 400mg PO. The primary endpoint (PFS in all comers) was superior with Elacestrant (HR = 0.70; P = .002). The co-primary endpoint of PFS in patients with ESR1 mutation was also improved with Elacestrant compared to SOC (HR = 0.55; P = .0005)